IQVIA (IQV)
NYSEHealth CareMedical - Diagnostics & ResearchSnapshot 2026-11-05
$264.88+0.41%
Close 2026-11-05 · 1-day change
NYSEHealth CareMedical - Diagnostics & ResearchSnapshot 2026-11-05
QuarterlyIQ Insights · IQV
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How this business ranks within health care on a research-validated quality screen. As of 2026-11-04.
The screen ranks IQV against its sector on four durable signals: share dilution, return on capital, free-cash-flow yield, and FCF margin. Historically the highest-quality names tended toward better typical outcomes and fewer bad years over multi-year holds (strongest at three years, modest at one), and that pattern showed up even before the price moved. It characterizes business quality, not price direction.
Each leg is a sector-relative percentile (higher is better); 4 of 4 legs were available for this name. The composite is built from these four; the raw value follows each percentile for context.
A forward quality tilt, not a price prediction, and context for your own research rather than a recommendation. Not investment advice.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 53% of the time over the next year (vs 42% for the rest of the cohort, n=10089).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Met or beat guidance 100% of the last 5 guided quarters · 3.0% avg surprise
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Full-Year 2026 Guidance The company is raising its full-year 2026 guidance for revenue to be between $17,350 million and $17,500 million, for Adjusted EBITDA to be between $4,025 million and $4,055 m…
Stated in 5 of 8 supplied quarters. Management reported: “Full-Year 2026 Guidance The company is raising its full-year 2026 guidance for revenue to be between $17,350 million and $17,500 million, for Adjusted EBITDA to be between $4,025 million and $4,055 million and for Adjusted Diluted Earnings per Share to be between $12.90 and $13.00.” “This revenue guidance now anticipates 250 basis points of contribution from acquisitions, including acquisitions the company expects to complete by the end of the year, and approximately 20 basis points of tailwind from foreign exchange.”
“Full-Year 2026 Guidance The company is raising its full-year 2026 guidance for revenue to be between $17,350 million and $17,500 million, for Adjusted EBITDA to be between $4,025 million and $4,055 m…”
“Full-Year 2026 Guidance To reflect stronger organic revenue growth, and changes in the M&A and foreign exchange impacts, the company is raising its full-year 2026 guidance for revenue to be between $…”
“Full-Year 2026 Guidance The company is reaffirming its full-year 2026 guidance for revenue to be between $17,150 million and $17,350 million, and for Adjusted EBITDA to be between $3,975 million and…”
“Full-Year 2026 Guidance For the full year of 2026, the company expects revenue to be between $17,150 million to $17,350 million.”
“Full-Year 2025 Guidance The company is reaffirming the midpoint of its full-year 2025 guidance and narrowing the ranges as follows: revenue expected to be between $16,150 million and $16,250 million,…”
Document Exhibit 99.1 IQVIA Reports Third-Quarter 2026 Results • Revenue $4,428 million, up 8.0% year-over-year, up 8.6% at constant currency • GAAP Net Income $350 million, Adjusted EBITDA $1,032 mi…
Stated in 4 of 8 supplied quarters. Management reported: “Investor Day IQVIA will host an Investor Day on Tuesday, December 1, 2026.” “This revenue guidance now anticipates 250 basis points of contribution from acquisitions, including acquisitions the company expects to complete by the end of the year, and approximately 20 basis points of tailwind from foreign exchange.”
Year-Over-Year Comparisons As previously disclosed, effective January 1, 2026, the company implemented a new, simplified organizational model to strengthen collaboration, enhance efficiency, and supp…
Stated in 3 of 8 supplied quarters. Management reported: “IQVIA is committed to using artificial intelligence responsibly, with AI-powered capabilities built on best-in-class approaches to privacy, regulatory compliance and patient safety, and delivering AI to the high standards of trust, scalability and precision demanded by the industry.” “IQVIA is committed to using artificial intelligence ("AI") responsibly, with AI-powered capabilities built on best-in-class approaches to privacy, regulatory compliance and patient safety, and delivering AI to the high standards of trust, scalability and precision demanded by the industry.”
Year-Over-Year Comparisons As previously disclosed, effective January 1, 2026, the company implemented a new, simplified organizational model to strengthen collaboration, enhance efficiency, and supp…
Stated in 3 of 8 supplied quarters. Management reported: “Year-Over-Year Comparisons As previously disclosed, effective January 1, 2026, the company implemented a new, simplified organizational model to strengthen collaboration, enhance efficiency, and support continued growth.” “Segment Reporting Effective January 1, 2026, the CSMS segment, which has become more closely related operationally to the TAS commercial offerings, and represents $788 million in 2025 revenue, is incorporated into the TAS segment, which is renamed Commercial Solutions.”
Build R&D Solutions bookings and contracted backlog, then convert backlog into revenue.
Over the trailing year it converted 1.92x of net income into operating cash flow. Historically, Health Care names rated robust grew net income 54% of the time over the next year (vs 44% for the rest of the cohort, n=2525).
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
17 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated volatile grew net income 45% of the time over the next year (vs 45% for the rest of the cohort, n=10076).
Not investment advice. As of 2026-11-05.
“Document Exhibit 99.1 IQVIA Reports Third-Quarter 2026 Results • Revenue $4,428 million, up 8.0% year-over-year, up 8.6% at constant currency • GAAP Net Income $350 million, Adjusted EBITDA $1,032 mi…”
“Document Exhibit 99.1 IQVIA Reports First-Quarter 2026 Results • Revenue of $4,151 million, up 8.4% year-over-year • GAAP Net Income of $274 million, Adjusted EBITDA of $932 million • GAAP Diluted Ea…”
“Document Exhibit 99.1 IQVIA Reports Fourth-Quarter and Full-Year 2025 Results; Issues Full-Year 2026 Guidance • Revenue of $4,364 million for the fourth quarter, $16,310 million for the full year • G…”
““R&DS continued to perform well, with strong demand across all customer segments and improved client decision timelines leading to 13 percent growth in net bookings year-over-year.”
“Year-Over-Year Comparisons As previously disclosed, effective January 1, 2026, the company implemented a new, simplified organizational model to strengthen collaboration, enhance efficiency, and supp…”
“IQVIA is committed to using artificial intelligence responsibly, with AI-powered capabilities built on best-in-class approaches to privacy, regulatory compliance and patient safety, and delivering AI…”
“IQVIA is committed to using artificial intelligence ("AI") responsibly, with AI-powered capabilities built on best-in-class approaches to privacy, regulatory compliance and patient safety, and delive…”
“Year-Over-Year Comparisons As previously disclosed, effective January 1, 2026, the company implemented a new, simplified organizational model to strengthen collaboration, enhance efficiency, and supp…”
“Year-Over-Year Comparisons As previously disclosed, effective January 1, 2026, the company implemented a new, simplified organizational model to strengthen collaboration, enhance efficiency, and supp…”
“Segment Reporting Effective January 1, 2026, the CSMS segment, which has become more closely related operationally to the TAS commercial offerings, and represents $788 million in 2025 revenue, is inc…”